Emerging Tech
Insilico and SK Biopharm Advance AI Drug Discovery
Insilico Medicine's lead drug, INS018_055, reached Phase II trials in 2026, marking it as the first generative AI-designed drug for an AI-discovered target to achieve this milestone.
Arjun Mehta·June 22, 2026
